Please login to the form below

Not currently logged in
Email:
Password:

Merck KGaA appoints biosimilar head

Simon Sturge joins from Boehringer Ingelheim
Simon Sturge, Merck KGaA

Simon Sturge is to leave his role at Boehringer Ingelheim to join fellow German healthcare company Merck KGaA as head of its new biosimilars unit.

From March 1, Sturge will run the company's biosimilars division, which was set up in 2012 to develop copies of biological treatments with a focus on oncology and inflammatory disorders. 

Based in Canton de Vaud, Switzerland, the unit will include both in-house and partnership-based development to create biosimilars, which are seen as a major growth area over the next few years as patents for biological medicines expire.

Sturge is currently head of biopharmaceuticals at Boehringer, where his responsibilities include biosimilars.

His prior experience in pharma includes several CEO positions, such as Vernalis, Lonza Biologics and Celltech Biologics.

With his appointment, Sturge succeeds Thierry Hulot, who created Merck KGaA's biosimilars unit but later took over responsibility for global manufacturing and supply for its pharma unit Merck Serono.

21st February 2014

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

We are industry-leading thinkers when it comes to education. We use the latest academic thinking on the psychology of behaviour...

Latest intelligence

Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...
Emotional Intelligence and Blended Learning in Healthcare
EI and emotional selling are rising up the agenda when it comes to healthcare training. This article outlines how blended learning approaches can help put them into action....

Infographics